jiac284.pdf
766.2 KB
Oxford Journal of Infectious Diseases (November 2022 issue Drop 1 of 2)
In this months issue of the OJID, there is one paper that really stood out on Virus Replicon Particle Vaccines (VRPV's).
So?
Well this is the tech that J&J and AstraZeneca used in their vaxes. A drop specifically on this tech will follow shortly.
1) Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines
2) Cytomegalovirus Viremia Predicts Postdischarge Mortality in Kenyan HIV-Exposed Uninfected Children
3) Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial
4) Lassa Virus Replicon Particle Vax Protects Strain 13/N Guinea Pigs Against Challenge with Diverse Viral Strains
5) Delta Infection After Vax Elicits Potent Immunity to Omicron
6) Cov19 Vax Effectiveness Against SARS Cov2 Infection in the United States: Study of Repeat Blood Donors
In this months issue of the OJID, there is one paper that really stood out on Virus Replicon Particle Vaccines (VRPV's).
So?
Well this is the tech that J&J and AstraZeneca used in their vaxes. A drop specifically on this tech will follow shortly.
1) Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines
2) Cytomegalovirus Viremia Predicts Postdischarge Mortality in Kenyan HIV-Exposed Uninfected Children
3) Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial
4) Lassa Virus Replicon Particle Vax Protects Strain 13/N Guinea Pigs Against Challenge with Diverse Viral Strains
5) Delta Infection After Vax Elicits Potent Immunity to Omicron
6) Cov19 Vax Effectiveness Against SARS Cov2 Infection in the United States: Study of Repeat Blood Donors
👍1
jiac153.pdf
591.3 KB
Oxford Journal of Infectious Diseases (November 2022 issue Drop 2 of 2)
Something else I noticed about this issue, was the amount of truly interesting papers, that were denied access to the general public by an academic institution wall, that was far more than usual around 20 in total?
1) Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
2) SARS-CoV-2 Infection Causes Hyperglycemia in Cats
3) Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection
4) Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis
5) Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
6) Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients
Something else I noticed about this issue, was the amount of truly interesting papers, that were denied access to the general public by an academic institution wall, that was far more than usual around 20 in total?
1) Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
2) SARS-CoV-2 Infection Causes Hyperglycemia in Cats
3) Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection
4) Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis
5) Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
6) Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients
212373481.pdf
2.6 MB
Virus Replicon Particle Vaccines (VRPV's): The forgotten alternative technology for gene based vaccine / treatment delivery.
In this drop are a series of papers on Virus Replicon Particle Vaccines (VRPV's) and their continued use / experimentation, as a vaccine delivery system and the vector that was favoured by Johnson & Johnson and AstraZeneca.
These use a viral outer shell, instead of a synthetic lipid nanoparticle, to encapsulate the mRNA / mDNA and deliver it into the body and is seen as a more natural and likely far more successful delivery system, specifically with regards to mDNA (modified, also referred to as Recombinant, DNA) based technologies.
These mDNA based vaccines, are already in circulation btw, as it was mDNA that AZ used, with J&J opting for using mRNA in their VRPV technology.
In this drop are a series of papers on Virus Replicon Particle Vaccines (VRPV's) and their continued use / experimentation, as a vaccine delivery system and the vector that was favoured by Johnson & Johnson and AstraZeneca.
These use a viral outer shell, instead of a synthetic lipid nanoparticle, to encapsulate the mRNA / mDNA and deliver it into the body and is seen as a more natural and likely far more successful delivery system, specifically with regards to mDNA (modified, also referred to as Recombinant, DNA) based technologies.
These mDNA based vaccines, are already in circulation btw, as it was mDNA that AZ used, with J&J opting for using mRNA in their VRPV technology.